Circulating Tumor Cell Clusters, Doublets Do Not Inform Patient Care in Metastatic Breast Cancer
Total number of CTCs, rather than the presence of clusters, may be more prognostically important.
Diagnosis & Disease Information
Liquid Biopsy for Detecting MSI-High Status Found Concordant With Tissue-Based Testing
The new findings may extend the availability of MSI detection to all patients regardless of it they have tissue available for testing.
Biomarker Analysis Paves the Way for Targeted Therapies in Prostate Cancer
Genomic profiling reveals the prevalence of various actionable mutations in advanced prostate cancer.
Quantifying Driver Alterations in BCR-ABL1-Negative Myeloproliferative Neoplasms
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
Use of Pathogenic BRCA1/2 Alterations as Pan-Cancer Biomarkers for Therapy Selection May Not be Appropriate
In this study, the degree of homologous recombination deficiency was not predictable across cancer types using BRCA1/2 status.
HIV-Induced Expression of PD-L1 on Regulatory B Cells May Promote AIDS-Related NHL
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Are CTCs A Reliable Metric for Patient Stratification in Cancer?
It is still unknown whether liquid biopsies are a reliable mechanism for determining disease prognosis outside of prostate cancer.
Immunohistochemistry to Assess MET Status Is a Poor Screen for Actionable MET Alterations in Lung Adenocarcinoma
The results of this study were independent of whether MET positivity by immunohistochemistry was determined using an H-score cutoff of 300 or at least 200.
A Novel Resistance Mechanism to Osimertinib May Represent a New Therapeutic Target
For patients with advanced lung cancer characterized by an EGFR-activating mutation that has progressed on osimertinib, treatment decision making is challenging.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...